NCT00329160

Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease

A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Long-term Treatment of Hypercholesterolaemic Subjects With Coronary Heart Disease as Measured by Intravascular Ultrasonography

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 214 (actual)
• Sponsor: AstraZeneca · Industry
• Sex: All
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this study is to evaluate that 76 weeks of treatment with rosuvastatin calcium 2.5-20 mg results in no progression of coronary artery atherosclerotic volume as measured by intravascular ultrasonography (IVUS) imaging in hypercholesterolaemic subjects with coronary heart disease (CHD).

Conditions

• Hypercholesteremia

Interventions

Type	Name	Description
DRUG	Rosuvastatin	2.5-20 mg
DRUG	HMG CoA inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A

Timeline

• Start date: 2005-10-01
• Primary completion: 2008-10-01
• Completion: 2008-10-01
• First posted: 2006-05-24
• Last updated: 2011-08-31
• Results posted: 2011-07-15

Locations

27 sites across 1 country: Japan